Phase 2 Colorectal Cancer Trial, Recruiting NCT07562490 Sponsor: Fudan University Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT07562490
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any sex
  • People with an activity and health status score (called ECOG) rated 0, 1, or 2, meaning they are able to carry out at least some daily activities, with an expected survival of more than 3 months
  • People who have been diagnosed through laboratory testing with high-risk stage II colorectal cancer after surgery (a specific post-surgical cancer stage classification)
  • People whose blood test for circulating tumour DNA (ctDNA, tiny fragments of cancer-related DNA in the bloodstream) came back positive about one month after surgery
  • People with an expected survival of more than 12 months
  • People who are able to understand the study and are willing to sign a consent form agreeing to take part (either personally or through a legally authorised representative or guardian)

Who may not be able to join:

  • People who received cancer treatment (such as chemotherapy or radiation) before their surgery
  • People who received a blood transfusion during surgery or in the two weeks before surgery
  • People who are pregnant or breastfeeding, or people capable of having children who are not using adequate birth control
  • People who have had another cancer diagnosed within the past five years, with the exception of certain treated early-stage cervical or non-melanoma skin cancers
  • People who have uncontrolled brain tumours or cancer that has spread to the brain or nervous system, or who have significant pressure in the skull or neurological or psychiatric symptoms related to this
  • People with serious or uncontrolled ongoing health conditions, including: unstable heart conditions (such as heart attack, heart failure, unstable chest pain, fluid around the heart, or irregular heartbeat) within the six months before joining; diagnosed neurological or psychiatric conditions such as dementia or seizure disorders; severe or uncontrolled infections; a blood-clotting disorder called DIC or a significant tendency to bleed; or major loss of function in important organs
  • People who, in the opinion of the medical team running the trial, have any other condition that would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-18017312703

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Patient's 2-year Progression-Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov